Description: PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Home Page: phasebio.com
1 Great Valley Parkway
Malvern,
PA
19355
United States
Phone:
610 981 6500
Officers
| Name | Title |
|---|---|
| Mr. Jonathan P. Mow MBA | Pres, CEO & Director |
| Dr. John S. Lee M.D., Ph.D. | Chief Medical Officer |
| Mr. Lawrence Perkins | Chief Restructuring Officer & Principal Financial Officer |
| Ms. Susan Elizabeth Arnold Ph.D. | Sr. VP of Technical Operations |
| Mr. Kristopher L. Hanson | SVP, Gen. Counsel & Corp. Sec. |
| Mr. Glen G. Burkhardt | Sr. VP of HR |
| Ms. Lauren Richardson | Global Head of Regulatory Affairs & Quality Assurance |
| Mr. Jonathan J. Birchall | Chief Commercial Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 26.18 |
| Price-to-Sales TTM: | 1.5847 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 60 |